Intraoral Subsite, Histopathological Subtype, and Completeness of Pathological Characterization as Determinants of Cancer‐Specific Mortality in Minor Salivary Gland Carcinoma: A Population‐Based Competing‐Risks Analysis of 5820 Tumors
Clinical and Experimental Dental Research · 2026-12 · 12 (6)
DOI: 10.1002/cre2.70511 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dental Research, online erschienen am 17.11.2026. Verfasst von Zaidoon Jasim Rmaidh und 2 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To quantify how completely intraoral minor salivary gland carcinomas are characterized pathologically across subsites, and whether subsite and subtype predict cancer‐specific death after accounting for characterization, competing mortality, and stage. Materials and Methods SEER cohort (17 registries, 2000–2023) of 5820 tumors in 5777 patients. Cause‐specific Cox, Fine‐Gray, and Lunn‐McNeil models adjusted for age, sex, race, subtype, grade, stage, era, and treatment were refitted without treatment and after excluding unclassified histology and unrecorded grade. Cause‐of‐death coding was checked by relative survival.
Results
Unclassified histology ranged from 8.7% (retromolar area) to 57.5% (mobile tongue) and unrecorded grade from 23.1% to 61.8% (both p < 0.001); unclassified histology was itself prognostic (hazard ratio 2.95, 95% CI 2.37–3.68). Ten‐year cancer mortality ranged from 10.1% (buccal mucosa) to 35.1% (mobile tongue; p < 0.001); adjusted hazards were 2.03 (1.60–2.57) for mobile tongue, 2.01 (1.58–2.55) for floor of mouth, and 1.70 (1.26–2.30) for gingiva/alveolus. After excluding unclassified histology and unrecorded grade, floor of mouth (2.20, 1.48–3.26) and gingiva/alveolus (2.53, 1.47–4.35) persisted, whereas the mobile‐tongue estimate became imprecise (1.61, 0.86–3.01). Other‐cause mortality overtook cancer mortality at 9.4 years (13.2 years without a prior malignancy); 27.1% of other‐cause deaths were second malignancies. Conditional 5‐year cancer mortality in 10‐year survivors was 12.7% for adenoid cystic and 1.2% for mucoepidermoid carcinoma. Machine learning gave no meaningful gain over logistic regression.
Conclusions
Completeness of pathological characterization in registry data is patterned by anatomy and strongly prognostic, so anatomical prognosis and registry documentation are entangled; it is not a measure of diagnostic quality. Floor of mouth and gingiva/alveolus are robust subsite determinants of cancer death; the mobile‐tongue excess cannot be separated from incomplete characterization. Competing mortality is substantial, largely from second malignancy. Findings may help inform risk‐adapted surveillance, but cancer‐specific mortality alone cannot define its intensity.
Zitieren
APA
Rmaidh, Z. J., Mafrachi, A., & Alghzawi, H. M. (2026). Intraoral Subsite, Histopathological Subtype, and Completeness of Pathological Characterization as Determinants of Cancer‐Specific Mortality in Minor Salivary Gland Carcinoma: A Population‐Based Competing‐Risks Analysis of 5820 Tumors. Clinical and Experimental Dental Research, 12(6). https://doi.org/10.1002/cre2.70511
Vancouver
Rmaidh ZJ, Mafrachi A, Alghzawi HM. Intraoral Subsite, Histopathological Subtype, and Completeness of Pathological Characterization as Determinants of Cancer‐Specific Mortality in Minor Salivary Gland Carcinoma: A Population‐Based Competing‐Risks Analysis of 5820 Tumors. Clinical and Experimental Dental Research. 2026;12(6). doi:10.1002/cre2.70511
BibTeX
@article{Rmaidh2026,
author = {Rmaidh, Zaidoon Jasim and Mafrachi, Ammar and Alghzawi, Hamzah M.},
title = {Intraoral Subsite, Histopathological Subtype, and Completeness of Pathological Characterization as Determinants of Cancer‐Specific Mortality in Minor Salivary Gland Carcinoma: A Population‐Based Competing‐Risks Analysis of 5820 Tumors},
journal = {Clinical and Experimental Dental Research},
year = {2026},
volume = {12},
number = {6},
doi = {10.1002/cre2.70511}
}
EUVIMED